Bapineuzumab - IV every 13 weeks is indeed the less frequent IV dosing but Wyeth/Elan have a subcutaneous formulation (in phase II), which uses weekly injections and Bapineuzumab might end up with this formulation in order to reduce AE.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.